Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 4/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577935 | 0.91 | SIGMAR1 (0.48) | DRD2ACHEMEN1KMT2ABCHE | |
| SCHEMBL5577284 | 0.91 | MCHR1 (0.43) | ACHEBACE1MEN1KMT2ABCHE | |
| SCHEMBL5577994 | 0.91 | MEN1 (0.48) | DRD2ACHEBACE1MEN1KMT2A | |
| SCHEMBL5577266 | 0.89 | MEN1 (0.46) | MEN1KMT2AATMMAPK1SIGMAR1 | |
| SCHEMBL5577438 | 0.88 | KDM4E (0.44) | DRD2ACHEBACE1MEN1KMT2A | |
| SCHEMBL5577707 | 0.87 | MEN1 (0.45) | ACHEBACE1MEN1KMT2ABCHE | |
| SCHEMBL5577830 | 0.86 | MEN1 (0.49) | DRD2ACHEBACE1MEN1KMT2A | |
| SCHEMBL5577258 | 0.85 | RECQL (0.54) | DRD2ACHEMEN1KMT2ABCHE | |
| SCHEMBL5577328 | 0.85 | LMNA (0.44) | ACHEBACE1MEN1KMT2ABCHE | |
| SCHEMBL5577766 | 0.84 | APLNR (0.48) | ACHEMEN1KMT2AATMSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | DRD2 4468/4885ACHE 1504/4885BACE1 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.